Avidity Biosciences, Inc.
RNA$3.40B
Mid CapNASDAQPharmaceutical Preparations🇺🇸North AmericaSAN DIEGO391 employees
Drugs in Pipeline
5
Phase 3 Programs
2
Upcoming Catalysts
3
Next Catalyst
Aug 15, 2026
10wMarket Overview
Stock performance and key metrics
RNA News
Catalyst Timeline
3 upcoming, 0 past
Drug Pipeline
AOC 1001 (del-desiran)
DM1
AOC-1020
Facioscapulohumeral Muscular Dystrophy
AOC 1044
Duchenne Muscular Dystrophy
AOC 1001
DM1
AOC 1020
FSHD
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AOC 1001 (del-desiran) | Phase 3 | DM1 | - | - |
AOC-1020 | Phase 3 | Facioscapulohumeral Muscular Dystrophy | - | - |
AOC 1044 | Phase 2 | Duchenne Muscular Dystrophy | - | - |
AOC 1001 | Phase 2 | DM1 | - | - |
AOC 1020 | Phase 2 | FSHD | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply